Uncategorized

Odyssey, on second try, snags $279M in an IPO

After withdrawing its initial filing last year, the immune drugmaker rebounded and added to a recent run of sizable new biotech stock offerings.

Read More

Published

on

After withdrawing its initial filing last year, the immune drugmaker rebounded and added to a recent run of sizable new biotech stock offerings.

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version